Ischemic heart disease: metabolic approaches to management.

Carl J Pepine, Daniel F Pauly

Journal: Clinical cardiology 2004;27(8):439-41

PMID: 15346837

Free Full Text on PubMed Central View on PubMed

Abstract

The number of patients with coronary artery disease and its risk factors is increasing in Western nations. New treatments for these patients may soon include a class of agents known as the metabolic modulators. This group of agents consists of the partial fatty acid oxidation inhibitors trimetazidine and ranolazine, as well as dichloroacetate, which promotes carbohydrate utilization. Metabolic modulators also include the nutriceuticals L-carnitine and D-ribose. The available evidence regarding the benefits of each of these five agents is reviewed.

Address: University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida 32610, USA. [email protected]

DOI: 10.1002/clc.4960270802

Link outs

Free resources

Full Text Sources:

MeSH Terms: Acetanilides, Cardiovascular Agents, Carnitine, Dichloroacetic Acid, Energy Metabolism, Humans, Myocardial Ischemia, Oxidation-Reduction, Piperazines, Ranolazine, Ribose, Trimetazidine